Paul Rhodes, PhD
Co-Founder & Chief Executive Officer (CEO)
Dr. Rhodes defines the vision for Specific’s novel and important applications, and leads the identification and development of the company’s most important collaborative clinical relationships. Dr. Rhodes also established Specific’s first overseas office in the BioData Innovation Centre on the grounds of the Wellcome Trust Genome Campus, which houses the Sanger Institute.
Prior to Specific, Dr. Rhodes founded Evolved Machines, where he was PI for the DARPA RealNose program, directing a team of 8 universities and corporations to deliver an end-to-end artificial olfaction device capable of canine-competitive sensitivity in real-world conditions, which fostered development of Specific’s fundamental technology, which can be considered a form of artificial olfaction. During this project Dr. Rhodes oversaw the successful development of the first integrated nanotube FET sensor array, along with advances in the engineering of the Suslick sensor that is the heart of the Specific’s products. Dr. Rhodes’ received an AB in Physics magna cum laude from Harvard University, an MS in Physics from Stanford University, and a PhD in Neuroscience from NYU Medical School.
Chief Financial Officer (CFO)
Mr. Ek is an industry veteran with over 20 years in public and private corporate financial leadership. Mr. Ek had served since 2019 as the Chief Financial Officer of public company GenMark, overseeing its rapid growth to $200M in annual sales, and the process that led to its purchase by Roche Diagnostics for $1.8B in Q2 of this year. Mr. Ek had previously served as GenMark’s VP of Finance and Controller since November 2013. Prior to joining GenMark, Mr. Ek was Vice President and International Controller at Affymetrix and Corporate Controller at eBioscience prior to its sale to Affy. He began his career as a CPA at Ernst and Young, in the audit and advisory practice where he supported the successful initial public offerings of several San Diego life science firms.
Mr. Ek holds a B.S. in finance from Brigham Young University, a Masters in Accountancy from the University of Notre Dame’s Mendoza College of Business, and is a CPA.
Co-Founder & Chief Operations Officer (COO)
Ray Martino is COO and a co-founder of Specific Diagnostics. Ray has contributed in both technical and business capacities as Specific moved from research through product development on to the commercial stage.
Previously Ray was General Manager of the mobile and wireless business division at Symbol Technologies where he held various roles as the company grew from under $20M in sales to over $2B before being acquired by Motorola in 2007, after which Ray was CTO of Motorola’s enterprise business. As a pioneer of mobile computers and WiFi, Ray led the engineering, marketing and sales teams that were the creators and first go-to-market WiFi products including many first-in-the-world, category-creating products including: the world’s first mobile computer with a wireless network (long before iPhones), the world’s first wireless network switch and the world’s first commercial wearable mobile computing system.
Chief Commercial Officer (CCO)
Tony Bazarko has served as Chief Commercial Officer of Specific Diagnostics since October of 2020. Prior to joining Specific Dx he most recently held the position of Vice President, Commercial Development for the Americas and the General Manager of Canada at Danaher Corporation’s subsidiary Leica Biosystems. Mr. Bazarko Joined Leica as the Vice President of Sales in 2016.
Prior to Danaher, Mr. Bazarko held the positions of Senior Director, Strategic Affairs for North America and Senior Director of the Commercial Sales and Marketing for Life Science division at Roche Diagnostics Corporation. Mr. Bazarko also served in various leadership roles at Life Technologies and Fisher Scientific International. Mr. Bazarko holds a B.S. in Biology from Indiana University and his M.B.A from Northwestern’s Kellogg School of Management.